<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02487160</url>
  </required_header>
  <id_info>
    <org_study_id>SBL-INI-02-13</org_study_id>
    <nct_id>NCT02487160</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the Lenstec SBL-3 Multifocal Intraocular Lens</brief_title>
  <official_title>Clinical Evaluation of the Lenstec SBL-3 Multifocal Intraocular Lens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lenstec Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lenstec Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and performance of the SBL-3 intraocular&#xD;
      lens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety (adverse events) and performance (visual&#xD;
      acuity, spectacle independence) of the SBL-3 intraocular lens.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>photopic, distance corrected, monocular near visual acuity</measure>
    <time_frame>1 year following implantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>presence or absence of adverse events</measure>
    <time_frame>1 year following implantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>photopic, distance corrected, monocular intermediate visual acuity</measure>
    <time_frame>1 year following implantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>photopic, best corrected, monocular distance visual acuity</measure>
    <time_frame>1 year following implantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who are independent of spectacles</measure>
    <time_frame>1 year following implantation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">510</enrollment>
  <condition>Cataracts</condition>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>SBL-3 multifocal intraocular lens</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The SBL-3 intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control monofocal intraocular lens</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Control intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SBL-3 multifocal intraocular lens</intervention_name>
    <description>The SBL-3 intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group</description>
    <arm_group_label>SBL-3 multifocal intraocular lens</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control monofocal intraocular lens</intervention_name>
    <description>The Control intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group</description>
    <arm_group_label>Control monofocal intraocular lens</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥ 22 years of age, of any race and either gender&#xD;
&#xD;
          2. Operable, age related cataract grade in both eyes&#xD;
&#xD;
          3. Patients who require an intraocular lens (IOL) power in the range of 15 D - 30 D only&#xD;
&#xD;
          4. Able to comprehend and sign a statement of informed consent&#xD;
&#xD;
          5. Calculated lens power within the available supply range&#xD;
&#xD;
          6. Planned cataract removal by phacoemulsification&#xD;
&#xD;
          7. Potential postoperative visual acuity of 0.2 Logarithm of the Minimum Angle of&#xD;
             Resolution (logMAR) or better in both eyes&#xD;
&#xD;
          8. In good general and ocular health&#xD;
&#xD;
          9. Patients with preoperative astigmatism ≤1.0 D Note: Corneal incisions made to reduce&#xD;
             astigmatism will not be allowed during the course of the study.&#xD;
&#xD;
         10. Clear intraocular media other than cataract in study eyes&#xD;
&#xD;
         11. Preoperative Best Corrected Distance Visual Acuity (BCDVA) worse than 0.2 logMAR&#xD;
&#xD;
         12. The subject must be able to undergo second eye surgery between 7 days and 30 days of&#xD;
             the first eye surgery&#xD;
&#xD;
         13. Able to competently complete testing&#xD;
&#xD;
         14. Willing and able to attend study visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous intraocular surgery&#xD;
&#xD;
          2. Preoperative photopic pupil size of &lt; 2.75 mm&#xD;
&#xD;
          3. Previous corneal refractive surgery&#xD;
&#xD;
          4. Any inflammation or edema (swelling) of the cornea&#xD;
&#xD;
          5. Subjects with diagnosed degenerative visual disorders (e.g. macular degeneration or&#xD;
             other retinal disorders ) that are predicted to cause future acuity losses to a level&#xD;
             worse than 0.2 logMAR&#xD;
&#xD;
          6. Subjects who may reasonably be expected to require a secondary surgical intervention&#xD;
             at any time during the study (other than neodymium-doped yttrium aluminium garnet&#xD;
             (nd:YAG) capsulotomy)&#xD;
&#xD;
          7. Amblyopia&#xD;
&#xD;
          8. Clinically significant ptosis&#xD;
&#xD;
          9. Clinically severe corneal dystrophy (eg., epithelial, stromal, or endothelial&#xD;
             dystrophy), keratitis, keratoconjunctivitis, keratouveitis, keratopathy, or kerectasia&#xD;
&#xD;
         10. Diabetic Retinopathy&#xD;
&#xD;
         11. Extremely shallow anterior chamber, not due to swollen cataract&#xD;
&#xD;
         12. Microphthalmia&#xD;
&#xD;
         13. Previous retinal detachment&#xD;
&#xD;
         14. Previous corneal transplant&#xD;
&#xD;
         15. Severe dry eye&#xD;
&#xD;
         16. Recurrent severe anterior or posterior segment inflammation of unknown etiology&#xD;
&#xD;
         17. Systemic medications that may confound the outcome or increase the risk to the subject&#xD;
             in the opinion of the Investigator [tamsulosin hydrochloride (Flomax) or other&#xD;
             medications with similar side effects (floppy iris syndrome)]&#xD;
&#xD;
         18. Rubella or traumatic cataract&#xD;
&#xD;
         19. Iris neovascularization&#xD;
&#xD;
         20. Glaucoma (medically controlled or uncontrolled)&#xD;
&#xD;
         21. Aniridia&#xD;
&#xD;
         22. Chronic severe uveitis&#xD;
&#xD;
         23. Optic nerve atrophy&#xD;
&#xD;
         24. Corneal decompensation&#xD;
&#xD;
         25. Greater than 1.0 D of astigmatism&#xD;
&#xD;
         26. History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, etc.)&#xD;
&#xD;
         27. Pseudoexfoliation syndrome&#xD;
&#xD;
         28. Iris atrophy&#xD;
&#xD;
         29. Pupil abnormalities (e.g., corectopia)&#xD;
&#xD;
         30. Aniseikonia&#xD;
&#xD;
         31. An acute or chronic disease or illness that may confound the results of this&#xD;
             investigation (e.g., immunocompromised, connective tissue disease, clinically&#xD;
             significant atopic disease, diabetes, and any other such disease or illness)&#xD;
&#xD;
         32. Pregnant, lactating, or planning to become pregnant during the course of the trial&#xD;
             Note: Subjects who become pregnant during the study will not be discontinued; however,&#xD;
             data may be excluded from the effectiveness analyses because pregnancy can alter&#xD;
             refraction and visual acuity results.&#xD;
&#xD;
         33. Participation in another clinical trial within 30 days of study start&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Blake Harris</last_name>
    <role>Study Director</role>
    <affiliation>Lenstec Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eye Center South</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shepard Eye Center</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cape Coral Eye Center</name>
      <address>
        <city>Cape Coral</city>
        <state>Florida</state>
        <zip>33904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Centers of Florida</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newsom Eye &amp; Laser Center</name>
      <address>
        <city>Sebring</city>
        <state>Florida</state>
        <zip>33870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Eye Centers</name>
      <address>
        <city>Willmar</city>
        <state>Minnesota</state>
        <zip>56201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Center of Central PA</name>
      <address>
        <city>Allenwood</city>
        <state>Pennsylvania</state>
        <zip>17810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Care Specialists</name>
      <address>
        <city>Kingston</city>
        <state>Pennsylvania</state>
        <zip>18704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Eyecare Physicians</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loden Vision Center</name>
      <address>
        <city>Goodlettsville</city>
        <state>Tennessee</state>
        <zip>37072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kleiman/Evangelista Eye Center</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whitsett Vision Group</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Institute of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>June 25, 2015</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <last_update_submitted>October 17, 2018</last_update_submitted>
  <last_update_submitted_qc>October 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

